 |
|
Tetracycline and Epidermolysis Bullosa Simplex
A New Indication for One of the Oldest and Most Widely Used Drugs in Dermatology?
Arch Dermatol. 1999;135:981-982.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
WITHIN THE PAST 15 years, remarkable advances have been made in our understanding of each of the major types and subtypes of inherited epidermolysis bullosa (EB). These have included the more complete characterization of the breadth, severity, and relative frequency of cutaneous1 and extracutaneous2 manifestations within each EB type and subtype, estimations of the cumulative and interval risks for each known outcome or complication of the disease,3-5 determination of the prevalence and incidence of each major and minor phenotype within several geographically and ethnically distinct populations,6 and the elucidation of the molecular basis of most EB subtypes.7 Although eventually some of this knowledge may result in the successful development of beneficial gene therapies, at present there are no treatments available that appear to result in long-term reductions in blister counts or improvement in skin mechanical fragility in any form of this disease, despite numerous attempts with a variety of topical . . . [Full Text of this Article]
RELATED ARTICLE
Finasteride, 1 mg (Propecia), Is the Optimal Dose for the Treatment of Men With Male Pattern Hair Loss
Keith D. Kaufman
Arch Dermatol. 1999;135(8):989-990.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Treatment of Epidermolysis Bullosa Simplex (EBS) With Tetracycline
Veien and Buus
Arch Dermatol 2000;136:424-425.
FULL TEXT
|
